Cargando…

Alcohol dehydrogenase 4 is a TP53-associated gene signature for the prediction of prognosis in hepatocellular carcinoma

Tumor protein p53 (TP53) is one of the most frequently mutated genes in hepatocellular carcinoma (HCC), an event that has been associated with a poor prognosis. Therefore, availability of an accurate prognostic signature would be beneficial for improving therapeutic efficacy and patient prognosis. I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuan, Jiang, Hui-Hong, Wang, Zhen-Yu, Zhai, Bo, Lin, Mou-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677524/ https://www.ncbi.nlm.nih.gov/pubmed/36419756 http://dx.doi.org/10.3892/ol.2022.13589

Ejemplares similares

Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma
por: Kancherla, Venkatesh, et al.
Publicado: (2018)

Significance of TP53 Mutational Status-Associated Signature in the Progression and Prognosis of Endometrial Carcinoma
por: Chen, Ying, et al.
Publicado: (2022)

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
por: Guo, Chunguang, et al.
Publicado: (2022)

TP53/MicroRNA Interplay in Hepatocellular Carcinoma
por: Pollutri, Daniela, et al.
Publicado: (2016)

TP53 Mutation Related and Directly Regulated lncRNA Prognosis Markers in Hepatocellular Carcinoma
por: Zhang, Xiulei, et al.
Publicado: (2021)

TP53 mutation detected in circulating exosomal DNA is associated with prognosis of patients with hepatocellular carcinoma
por: Li, Yong, et al.
Publicado: (2022)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Identification and development of TP53 mutation-associated Long non-coding RNAs signature for optimized prognosis assessment and treatment selection in hepatocellular carcinoma
por: Chu, Chenghao, et al.
Publicado: (2023)

An Apoptotic Gene Signature for the Prognosis of Hepatocellular Carcinoma
por: Chen, Kunlun, et al.
Publicado: (2021)

Construction and Validation of a Reliable Six-Gene Prognostic Signature Based on the TP53 Alteration for Hepatocellular Carcinoma
por: Huo, Junyu, et al.
Publicado: (2021)

A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma
por: Xu, Feng, et al.
Publicado: (2020)

The TP53-Related Signature Predicts Immune Cell Infiltration, Therapeutic Response, and Prognosis in Patients With Esophageal Carcinoma
por: Zhang, Hongpan, et al.
Publicado: (2021)

Prognostic implications of alcohol dehydrogenases in hepatocellular carcinoma
por: Liu, Xiangye, et al.
Publicado: (2020)

Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA
por: Li, Xuerui, et al.
Publicado: (2020)

TP53 Mutation in Correlation to Immunohistochemical Expression of P53 Protein in Patients with Hepatocellular Carcinoma
por: Nikolova, Dafina, et al.
Publicado: (2018)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
por: Long, Junyu, et al.
Publicado: (2019)

Individualized prognosis stratification in muscle invasive bladder cancer: A pairwise TP53-derived transcriptome signature
por: Liu, Hua-Ping, et al.
Publicado: (2023)

Identification of Novel Characteristics in TP53-Mutant Hepatocellular Carcinoma Using Bioinformatics
por: Yang, Yang, et al.
Publicado: (2022)

Analysis of TP53 aflatoxin signature mutation in hepatocellular carcinomas from Guatemala: A cross‐sectional study (2016‐2017)
por: Alvarez, Christian S., et al.
Publicado: (2020)

TP53 variants in p53 signatures and the clonality of STICs in RRSO samples
por: Akahane, Tomoko, et al.
Publicado: (2022)

TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer
por: Zhang, Feng, et al.
Publicado: (2021)

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma
por: Rebbani, Khadija, et al.
Publicado: (2015)

Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma
por: Shi, Muqi, et al.
Publicado: (2020)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high‐risk subgroup represented by the co‐mutations of DDX3X‐TP53
por: Gao, Fan, et al.
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Analysis of Tp53 Codon 72 Polymorphisms, Tp53 Mutations, and HPV Infection in Cutaneous Squamous Cell Carcinomas
por: Loeb, Keith R., et al.
Publicado: (2012)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
por: Flynt, Erin, et al.
Publicado: (2020)

TP53 and its Regulatory Genes as Prognosis of Cutaneous Melanoma
por: Khan, Safir Ullah, et al.
Publicado: (2023)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
por: Abdel-Fattah, R., et al.
Publicado: (1998)

TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients
por: Di Vuolo, Valeria, et al.
Publicado: (2011)

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
por: Ye, Song, et al.
Publicado: (2017)

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma
por: Ye, Song, et al.
Publicado: (2022)

TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study
por: Tao, Yuting, et al.
Publicado: (2022)

PIK3CA and TP53 mutations predict overall survival of stage II/III colorectal cancer patients
por: Li, A-Jian, et al.
Publicado: (2018)

TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations
por: Abedi-Ardekani, Behnoush, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_oqvu4ajg9racltiuluhc77t0bk